Acrivon Therapeutics Inc (ACRV)

06:20 AM

Nuveen Asset Management LLC Sells 12,377 Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World

06:20 AM

May 31, 2025

Northern Trust Corp Has $706,000 Stock Position in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World

May 31, 2025

May 25, 2025

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Recommendation of “Buy” from Analysts - Defense World

May 25, 2025

May 21, 2025

Acrivon Therapeutics: Promising Clinical Developments and Strategic Focus Support Buy Rating - TipRanks

May 21, 2025

May 19, 2025

FY2025 EPS Estimate for Acrivon Therapeutics Cut by Analyst - Defense World

May 19, 2025

May 19, 2025

Q3 EPS Forecast for Acrivon Therapeutics Boosted by Analyst - Defense World

May 19, 2025

May 19, 2025

(ACRV) Investment Analysis and Advice - news.stocktradersdaily.com

May 19, 2025

May 18, 2025

Jones Trading Reaffirms Hold Rating for Acrivon Therapeutics (NASDAQ:ACRV) - Defense World

May 18, 2025

May 17, 2025

Acrivon Therapeutics (ACRV) Downgraded by Jones Trading | ACRV S - GuruFocus

May 17, 2025

May 17, 2025

Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch - Yahoo Finance

May 17, 2025

May 17, 2025

Oppenheimer Issues Pessimistic Forecast for Acrivon Therapeutics (NASDAQ:ACRV) Stock Price - Defense World

May 17, 2025

May 16, 2025

JonesResearch Downgrades Acrivon Therapeutics (ACRV) to Hold | ACRV Stock News - GuruFocus

May 16, 2025

May 16, 2025

Cantor Fitzgerald maintains Overweight on Acrivon Therapeutics stock By Investing.com - Investing.com South Africa

May 16, 2025

May 15, 2025

Acrivon Therapeutics (ACRV) Price Target Lowered by Oppenheimer - GuruFocus

May 15, 2025

May 15, 2025

Acrivon Therapeutics (ACRV) Price Target Lowered by Oppenheimer | ACRV Stock News - GuruFocus

May 15, 2025

May 15, 2025

Acrivon (ACRV) Advances Clinical Pipeline with Promising Data an - GuruFocus

May 15, 2025

May 15, 2025

Oppenheimer Cuts Price Target on Acrivon Therapeutics to $9 From $10, Keeps Outperform Rating - marketscreener.com

May 15, 2025

May 15, 2025

Acrivon Therapeutics, Inc.: Promising Clinical Data and Strategic Advancements Justify Buy Rating - TipRanks

May 15, 2025

May 15, 2025

Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights - GlobeNewswire

May 15, 2025

May 15, 2025

Cantor Fitzgerald maintains Overweight on Acrivon Therapeutics stock - Investing.com

May 15, 2025

May 15, 2025

Acrivon Therapeutics (ACRV) Projects Funding Through Mid-2027 | - GuruFocus

May 15, 2025

May 15, 2025

Acrivon Therapeutics (ACRV) Price Target Reduced by Oppenheimer - GuruFocus

May 15, 2025

May 15, 2025

Optimistic Outlook for Acrivon Therapeutics: Promising ACR-368 Results and Strategic Focus on Endometrial Cancer - TipRanks

May 15, 2025

May 15, 2025

Acrivon Therapeutics Reports Q1 2025 Progress and Financials - TipRanks

May 15, 2025

May 14, 2025

Acrivon Therapeutics (ACRV) Price Target Reduced by Oppenheimer | ACRV Stock News - GuruFocus

May 14, 2025

May 14, 2025

Acrivon Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 14, 2025

May 14, 2025

Acrivon Therapeutics Reports Positive ACR-368 Data for Endometrial Cancer and Appoints New Chief Medical Officer - Nasdaq

May 14, 2025

May 14, 2025

Breakthrough: Acrivon's Cancer Drug Shows 35% Response Rate in Resistant Endometrial Cancer Patients - Stock Titan

May 14, 2025

May 11, 2025

Acrivon Therapeutics (ACRV) to Release Earnings on Tuesday - Defense World

May 11, 2025

May 08, 2025

(ACRV) Investment Analysis - news.stocktradersdaily.com

May 08, 2025

May 06, 2025

Acrivon Therapeutics (NASDAQ:ACRV) Coverage Initiated by Analysts at Piper Sandler - Defense World

May 06, 2025

May 05, 2025

Here's Why Acrivon Therapeutics, Inc. (ACRV) Is a Great 'Buy the Bottom' Stock Now - Zacks Investment Research

May 05, 2025

May 05, 2025

Piper Sandler Initiates Coverage on Acrivon Therapeutics (ACRV) with Overweight Rating | ACRV Stock News - GuruFocus

May 05, 2025

May 05, 2025

Piper Sandler sets $6 target for Acrivon stock, rates it Overweight - Investing.com Nigeria

May 05, 2025

May 05, 2025

Piper Sandler sets $6 target for Acrivon stock, rates it Overweight By Investing.com - Investing.com South Africa

May 05, 2025

May 05, 2025

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Shares Sold by JPMorgan Chase & Co. - Defense World

May 05, 2025

May 04, 2025

Analysts Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) PT at $21.80 - Defense World

May 04, 2025

May 03, 2025

Cantor Fitzgerald Has Positive View of ACRV FY2025 Earnings - Defense World

May 03, 2025

May 02, 2025

Short Interest in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Decreases By 19.9% - Defense World

May 02, 2025

May 02, 2025

Acrivon Therapeutics’ major shareholder sells shares worth $1.02 million By Investing.com - Investing.com Canada

May 02, 2025

May 01, 2025

Major Shareholder Sells Massive Stake in Acrivon Therapeutics! - TipRanks

May 01, 2025

May 01, 2025

Acrivon Therapeutics’ major shareholder sells shares worth $1.02 million - Investing.com

May 01, 2025

May 01, 2025

You might want to take a look at Acrivon Therapeutics Inc (ACRV) now - Sete News

May 01, 2025

Apr 30, 2025

Acrivon Therapeutics Inc (ACRV)’s stock decline to 1.44 per share - uspostnews.com

Apr 30, 2025